RecruitingNot ApplicableNCT07241884

SakuraBead Used as Resorbable Embolic for Plantar Fascia Embolization


Sponsor

CrannMed

Enrollment

45 participants

Start Date

Oct 20, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This is a prospective, single center, double arm, randomized, unmasked, First in Human study that aims to evaluate the safety and effectiveness of SakuraBead™ resorbable embolization microspheres in adult patients suffering from pain secondary to plantar fasciitis.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Arterial Embolization and a medical device called Extracorporeal shockwave therapy for people with musculoskeletal diseases, plantar fascitis, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEArterial Embolization

Resorbable microspheres are delivered trans-arterially using a microcatheter or introducer sheath to the site of embolization where they will temporarily embolize the hypervascularity in the targeted region with preservation of normal arterial flow.

DEVICEExtracorporeal shockwave therapy

Extracorporeal shockwave therapy (ESWT) is a treatment using acoustic pulses to treat plantar fasciitis.


Locations(1)

Nano Medical Clinic

Tashkent, Uzbekistan, Uzbekistan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07241884


Related Trials